Small Peanut Doses Build Protection for Allergic Children, Study

Children with peanut allergies may not need large treatment doses to gain protection from accidental exposure, according to a study led by The Hospital for Sick Children (SickKids) and the Montreal Children’s Hospital. Published in the Journal of Allergy and Clinical Immunology – In Practice, the research shows that a very small maintenance dose of peanut oral immunotherapy (OIT) can help increase tolerance while reducing side effects and treatment withdrawal.

Peanut OIT aims to raise the amount of peanut that can be eaten before triggering an allergic reaction, protecting children from accidental ingestion. Traditional OIT starts with small doses that gradually increase until reaching a regular “maintenance” dose. However, the standard regimen often requires large quantities, extended treatment periods, and close monitoring, which can lead some participants to stop due to side effects or taste issues.

The study is the first to directly compare standard and reduced peanut OIT doses in children, demonstrating that smaller doses can still improve tolerance and make the approach more accessible. Researchers randomly assigned 51 children into three groups: low-dose (30 mg maintenance), standard-dose (300 mg maintenance), or avoidance (no OIT). Both treatment groups showed significant and comparable increases in their peanut reaction thresholds, proving that even small amounts can train the immune system effectively.

“We were excited to find that peanut OIT maintenance doses can be much lower than previously thought and still contribute to positive outcomes,” said Julia Upton, co-first author of the study. “The more options we have, the more we can support patients’ experience and provide meaningful, tailored care.” Children in the 30 mg group reported fewer adverse events than those in the 300 mg group, and none withdrew from treatment.

“This is a small enough dose that even children who do not like the taste can continue treatment,” added Thomas Eiwegger, co-senior author. He noted that the minimum beneficial dose may be even lower than 30 mg. Co-senior author Moshe Ben-Shoshan emphasized that “very small amounts of peanuts, that are associated with less reactions, could be used as effectively as large amounts,” suggesting this approach could make peanut OIT safer and more widely available.